Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Amongst the AdVita assets being acquired in this transaction, Relief will gain further pending intellectual property rights that may cover RLF-100TM inhaled formulation specifications and the potential application of inhaled Aviptadil in the treatment of Acute Respiratory Distress Syndrome (ARDS) and Checkpoint Inhibitor- induced Pneumonitis (CIP).

https://advita-lifescience.com/wp-content/uploads/20210120_PR_Relief_AdVita_EN.pdf

Maybe Relief should have never brought Javitt on in the first place as it seems like the Advita team is actually capable of publishing in a prestigious journal

https://www.nejm.org/doi/full/10.1056/NEJMc2000343

~Saroja, Y@h00 RLFTF finance conversations